Post-Traumatic Migraine and CGRP Treatment: Attorney Guide

James Wong — Founder & CEO, LienScripts | March 29, 2026 | 7 min read

Post-traumatic migraine treated with CGRP agents like Qulipta, Nurtec, and Aimovig documents TBI severity for personal injury attorneys. This guide explains why CGRP prescriptions are among the strongest pharmacological evidence of traumatic brain injury in settlement negotiations.

Post-traumatic migraine (PTM) is a secondary headache disorder that develops after traumatic brain injury, and when a neurologist prescribes a CGRP agent — Qulipta, Nurtec ODT, or Aimovig — that clinical decision documents that the patient's head trauma produced a neurological condition severe enough to require biologic-class intervention. For personal injury attorneys, a CGRP prescription is among the most powerful pieces of pharmacological evidence linking an accident to lasting brain injury.

• Post-traumatic migraine affects 30-90% of mild TBI patients, with up to 25% developing chronic migraine lasting beyond 12 months (Ashina et al., Lancet Neurology, 2021)
• CGRP agents — Qulipta (atogepant), Nurtec ODT (rimegepant), and Aimovig (erenumab) — represent the newest class of migraine-specific medications, prescribed only when standard treatments fail
• LienScripts covers all CGRP medications on pharmacy lien, and each case receives a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the full treatment escalation from OTC to biologic therapy
• According to James Wong, PharmD, founder of LienScripts, "A CGRP prescription in a post-traumatic migraine case tells the adjuster that this is not a simple headache — it is a neurological condition requiring specialist-level pharmacological management"
• The International Classification of Headache Disorders (ICHD-3) classifies PTM as a distinct diagnosis requiring documented temporal relationship to head trauma

Why CGRP Prescriptions Document TBI Severity

The decision to prescribe a CGRP agent is never first-line. Before a neurologist reaches for Qulipta, Nurtec, or an injectable like Aimovig, the patient has typically failed multiple standard treatments — OTC analgesics, triptans, and older preventives like topiramate or amitriptyline. Each failed step is documented in the medical record, creating an escalation timeline that maps directly to injury severity.

CGRP (calcitonin gene-related peptide) is a neuropeptide released during migraine attacks that causes vasodilation and neurogenic inflammation in the trigeminal system. The FDA approved the first CGRP antagonist in 2018, and the class now includes both oral gepants (daily or as-needed) and injectable monoclonal antibodies (monthly or quarterly). These medications were developed specifically for migraine — they have no analgesic properties for other pain types — making their prescription inherently diagnostic.

[!KEY] A CGRP prescription is inherently diagnostic: these medications treat only migraine through a migraine-specific mechanism. Their presence in the pharmacy record proves the treating neurologist diagnosed migraine, not merely "headache," and determined the condition warranted biologic-class therapy.

The Three CGRP Categories in PI Cases

Oral Gepants (Daily Prevention)

Qulipta (atogepant) is the only CGRP receptor antagonist with FDA approval exclusively for migraine prevention. Dosed daily at 30mg or 60mg, it creates a continuous pharmacy dispensing record — typically monthly refills that document ongoing neurological management.

Nurtec ODT (rimegepant) holds dual FDA approval for both acute treatment (as-needed) and preventive treatment (every other day). This dual role is particularly valuable in PI documentation because it shows the patient requires CGRP blockade for both attack treatment and prevention.

Injectable CGRP Antibodies (Monthly/Quarterly)

Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), and Vyepti (eptinezumab) are monoclonal antibodies that provide extended CGRP pathway blockade. These are typically prescribed when oral gepants are insufficient or when the neurologist determines more robust prevention is needed. Injectable CGRP antibodies generate monthly or quarterly pharmacy records documenting specialist-level care.

[!TIP] When reviewing a client's pharmacy records, look for the transition point from triptan or OTC use to a CGRP agent. That date marks the clinical determination that the post-traumatic migraine exceeded standard treatment thresholds — a powerful inflection point for demand narratives.

The Escalation Timeline as Evidence

The typical post-traumatic migraine medication trajectory follows a predictable pattern that mirrors injury severity:

1. Weeks 1-4: OTC analgesics (acetaminophen, ibuprofen) — initial conservative management
2. Months 1-3: Triptans (sumatriptan, rizatriptan) — prescription-level acute treatment
3. Months 2-6: Older preventives (topiramate, amitriptyline, propranolol) — daily prevention attempted
4. Months 3-12+: CGRP agents — biologic-class intervention after standard failures

Each step in this escalation represents a clinical determination that the prior treatment level was inadequate. The pharmacy record captures every step, creating a timeline that defense counsel cannot easily dismiss.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The escalation pattern from OTC to CGRP is the pharmacy equivalent of going from an urgent care visit to a neurosurgery referral — each step up documents that the condition is more severe than the previous treatment could manage."

Connecting CGRP Treatment to TBI Diagnosis

The ICHD-3 diagnostic criteria for post-traumatic headache require that the headache develops within seven days of head trauma (or within seven days of regaining consciousness). When combined with a CGRP prescription, attorneys can establish:

1. Temporal causation: The headache disorder began after the accident
2. Diagnostic specificity: A neurologist diagnosed migraine, not tension headache or cervicogenic headache
3. Severity threshold: Standard treatments failed, requiring biologic-class intervention
4. Chronicity: Ongoing CGRP prescriptions document that the condition persists months or years post-injury

This four-element framework makes CGRP-treated post-traumatic migraine one of the strongest medication-documented injury claims in personal injury.

[!KEY] Post-traumatic migraine treated with CGRP agents creates a four-layer evidence stack: temporal causation, diagnostic specificity, severity threshold, and chronicity documentation. Each CGRP refill reinforces all four elements simultaneously.

Defense Challenges to CGRP Treatment

"The Headaches Are Pre-Existing"

Defense may argue the patient had migraines before the accident. Counter: the pharmacy record shows when CGRP therapy began. If the patient used only OTC medications before the accident and escalated to CGRP agents after, the temporal relationship is clear. The MERIT report from LienScripts documents this pre-/post-accident medication comparison.

"CGRP Medications Are Overpriced"

Defense may challenge the cost of CGRP agents. Counter: these are FDA-approved, branded medications with no generic alternatives. The prescriber selected them because lower-cost options failed — a clinical necessity determination supported by the escalation record.

"The Patient Doesn't Need Ongoing Treatment"

Defense may argue treatment should have ended. Counter: migraine is a neurological condition, and post-traumatic migraine frequently becomes chronic (lasting beyond 12 months). The International Headache Society recognizes persistent post-traumatic headache as a distinct entity requiring ongoing management.

What Attorneys Should Do

1. Refer early for pharmacy lien coverage — CGRP medications cost $800-1,200/month at retail. LienScripts covers these medications on lien with zero upfront cost, ensuring the patient begins treatment immediately
2. Request the MERIT report — LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the complete medication escalation timeline, which strengthens the demand package
3. Coordinate with the treating neurologist — ensure the neurologist documents the temporal relationship between the accident and migraine onset, and the clinical rationale for CGRP escalation
4. Document failed prior therapies — each failed medication strengthens the case for CGRP necessity

Frequently Asked Questions

For lien-based coverage of CGRP medications for post-traumatic migraine, LienScripts provides pharmacy services for personal injury patients with no upfront cost.

Related Resources

• CGRP Medications: A Complete Guide for Personal Injury
• Qulipta (Atogepant): Preventive Migraine Treatment After a Personal Injury
• Nurtec ODT (Rimegepant): Dual Acute and Preventive Migraine Treatment
• Aimovig, Emgality, Ajovy, and Vyepti: Injectable CGRP Medications
• Migraine Medication Escalation and Settlement Value